Roche reports slightly better sales than predicted in Q1
In Q1 2021, pharmaceutical company Roche has had better sales than predicted, especially in terms of diagnostics and hemophilia drug Hemlibra.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
Swiss pharmaceutical giant Roche has had better sales than the company forecast in the first three months of the year, as diagnostics equipment and the hemophilia medicine Hemlibra in particular have sold surprisingly well, according to the firm's Q1 report.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Roche publishes new sclerosis data to keep Novartis at bay
For subscribers
